GlassScriptPhysician profile
Sangeetha Satyan
NPI 1447453915
$6,018.76
in general payments reported to CMS, 2019-2025
38 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $202 · 2021: $456 · 2022: $780 · 2023: $996 · 2024: $1,604 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,797 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,797.37 |
| Education | $111.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $503.28 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $493.69 | 2019-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $492.71 | 2019-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $365.67 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Akebia Therapeutics INC | $362.84 | 2019-2025 | Auryxia, Vafseo |
| Horizon Therapeutics Plc | $362.67 | 2020-2023 | Krystexxa |
| Amgen INC. | $313.63 | 2022-2025 | Tavneos, Uplizna |
| Bayer Healthcare Pharmaceuticals INC. | $310.53 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $273.97 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $251.00 | 2023-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $233.29 | 2020-2025 | Acthar |
| Genzyme Corporation | $225.43 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $224.81 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $214.01 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $184.14 | 2023-2025 | Benlysta, Jesduvroq |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sangeetha Satyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.